#Medsky🧪 #oncosky #pharmasky #Immunotherapy in cancer is often limited by adverse autoimmune effects incl T1D A study published in @jci-insight.bsky.social found #JAKinhibitor #ruxolitinib protects against ICI-T1DM in 🐁 & impairs T follicular helper cell differentiation in patients with ICI-T1DM.
July 22, 2025 at 1:05 PM
#Medsky🧪 #oncosky #pharmasky #Immunotherapy in cancer is often limited by adverse autoimmune effects incl T1D A study published in @jci-insight.bsky.social found #JAKinhibitor #ruxolitinib protects against ICI-T1DM in 🐁 & impairs T follicular helper cell differentiation in patients with ICI-T1DM.
Atopic Dermatitis (AD) is more than just dry skin—it's a complex immune failure.
We reviewed Abrocitinib, the new selective JAK1 inhibitor that is changing the game for moderate-to-severe eczema.
doi.org/10.2174/0115743624291067240307051246
#WeiPublications #Dermatology #Eczema #JAKinhibitor
We reviewed Abrocitinib, the new selective JAK1 inhibitor that is changing the game for moderate-to-severe eczema.
doi.org/10.2174/0115743624291067240307051246
#WeiPublications #Dermatology #Eczema #JAKinhibitor
January 3, 2026 at 11:40 PM
Atopic Dermatitis (AD) is more than just dry skin—it's a complex immune failure.
We reviewed Abrocitinib, the new selective JAK1 inhibitor that is changing the game for moderate-to-severe eczema.
doi.org/10.2174/0115743624291067240307051246
#WeiPublications #Dermatology #Eczema #JAKinhibitor
We reviewed Abrocitinib, the new selective JAK1 inhibitor that is changing the game for moderate-to-severe eczema.
doi.org/10.2174/0115743624291067240307051246
#WeiPublications #Dermatology #Eczema #JAKinhibitor
Filgotinib offers new promise for managing Crohn’s disease 🌟💊🌍 www.news-medical.net/news/2024120... #CrohnsDisease #Filgotinib #JAKInhibitor #ClinicalTrials #Gastroenterology #Health #Medical #PatientCare @thelancet.bsky.social
Filgotinib offers new promise for managing Crohn’s disease
Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's disease, achieving clinical and endoscopic remission in phase 3 trials. The ...
www.news-medical.net
December 9, 2024 at 1:34 AM
Filgotinib offers new promise for managing Crohn’s disease 🌟💊🌍 www.news-medical.net/news/2024120... #CrohnsDisease #Filgotinib #JAKInhibitor #ClinicalTrials #Gastroenterology #Health #Medical #PatientCare @thelancet.bsky.social
#AbbVie's fast-growing #JAKinhibitor #Rinvoq has been cleared for #alopeciaareata in the #EU, the first market for the #hairlossdisorder, adding to a lengthening list of approved indications for the blockbuster brand.
buff.ly/uSXtRiw
buff.ly/uSXtRiw
July 29, 2026 at 1:00 PM
#AbbVie's fast-growing #JAKinhibitor #Rinvoq has been cleared for #alopeciaareata in the #EU, the first market for the #hairlossdisorder, adding to a lengthening list of approved indications for the blockbuster brand.
buff.ly/uSXtRiw
buff.ly/uSXtRiw
New article to read! Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis.
➡️ No significant survival benefit but reassuring safety profile.
🔗 doi.org/10.1111/joim.70047
#dermatomyositis #JAKinhibitor @univlille.bsky.social
➡️ No significant survival benefit but reassuring safety profile.
🔗 doi.org/10.1111/joim.70047
#dermatomyositis #JAKinhibitor @univlille.bsky.social
November 24, 2025 at 3:28 PM
New article to read! Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis.
➡️ No significant survival benefit but reassuring safety profile.
🔗 doi.org/10.1111/joim.70047
#dermatomyositis #JAKinhibitor @univlille.bsky.social
➡️ No significant survival benefit but reassuring safety profile.
🔗 doi.org/10.1111/joim.70047
#dermatomyositis #JAKinhibitor @univlille.bsky.social
This report illustrates a case of combined consecutive bilateral occlusive vasculitis and cytomegalovirus (CMV) retinitis during treatment with upadacitinib, a selective Janus kinase (JAK1) inhibitor. A literature review is included.
bit.ly/cjo_JAK-inhi...
#Ophthalmology #Uveitis #JAKInhibitor
bit.ly/cjo_JAK-inhi...
#Ophthalmology #Uveitis #JAKInhibitor
Combined consecutive bilateral occlusive vasculitis and CMV retinitis in immunosuppression with JAK Inhibitor
Since their introduction in 2012, Janus kinase (JAK) inhibitors have transformed the
management of autoimmune diseases in both systemic and ophthalmological conditions.
However, their expanding use ha...
bit.ly
March 23, 2026 at 1:53 PM
This report illustrates a case of combined consecutive bilateral occlusive vasculitis and cytomegalovirus (CMV) retinitis during treatment with upadacitinib, a selective Janus kinase (JAK1) inhibitor. A literature review is included.
bit.ly/cjo_JAK-inhi...
#Ophthalmology #Uveitis #JAKInhibitor
bit.ly/cjo_JAK-inhi...
#Ophthalmology #Uveitis #JAKInhibitor
China aprueba el 1er genérico de upadacitinib (JAK) 🇨🇳
🐱🏍 +40 compañías compiten → más acceso y presión en precios en AR y dermatitis atópica.
📌 Solo informativo.
#Upadacitinib #JAKInhibitor #ChinaPharma #GenericDrugs #DengYueMed
🐱🏍 +40 compañías compiten → más acceso y presión en precios en AR y dermatitis atópica.
📌 Solo informativo.
#Upadacitinib #JAKInhibitor #ChinaPharma #GenericDrugs #DengYueMed
April 28, 2026 at 7:47 AM
China aprueba el 1er genérico de upadacitinib (JAK) 🇨🇳
🐱🏍 +40 compañías compiten → más acceso y presión en precios en AR y dermatitis atópica.
📌 Solo informativo.
#Upadacitinib #JAKInhibitor #ChinaPharma #GenericDrugs #DengYueMed
🐱🏍 +40 compañías compiten → más acceso y presión en precios en AR y dermatitis atópica.
📌 Solo informativo.
#Upadacitinib #JAKInhibitor #ChinaPharma #GenericDrugs #DengYueMed
China NMPA Conditionally Approves Golixitinib Capsules for Market
📩 info@dengyuemed.com
🔗https://dengyuemed.com
#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs
📩 info@dengyuemed.com
🔗https://dengyuemed.com
#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs
October 29, 2025 at 2:45 AM
China NMPA Conditionally Approves Golixitinib Capsules for Market
📩 info@dengyuemed.com
🔗https://dengyuemed.com
#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs
📩 info@dengyuemed.com
🔗https://dengyuemed.com
#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs
#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I
zurl.co/ovP8I
AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE
The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population
pmlive.com
April 16, 2025 at 7:47 AM
#dermatology #skindisease #MHRA #Anzupgo #delgocitinib #eczemacream #handeczema #chronichandeczema #LEOPharma #UKMHRA #topicalJAKinhibitor #JAKinhibitor #phase3clincialtrials #DELTA1clincialtrial #DELTA2clinicaltrial #DELTA3openlabelextensiontrial #NICE #NHS
pf-media.co.uk/news/mhra-gr...
pf-media.co.uk/news/mhra-gr...
MHRA grants marketing authorisation for LEO Pharma’s eczema cream - Pf Media
The MHRA has granted marketing authorisation for LEO Pharma’s cream for the treatment of patients with moderate to severe chronic hand eczema.
pf-media.co.uk
December 6, 2024 at 10:36 AM
I fucked up big time.
A snafu with my meds (which I now know was entirely my fault) has my next refill a week out. In the meantime I've been out since Sunday.
And JAKInhibitor withdrawal is the worst experience I've ever had.
A snafu with my meds (which I now know was entirely my fault) has my next refill a week out. In the meantime I've been out since Sunday.
And JAKInhibitor withdrawal is the worst experience I've ever had.
March 7, 2024 at 4:07 PM
I fucked up big time.
A snafu with my meds (which I now know was entirely my fault) has my next refill a week out. In the meantime I've been out since Sunday.
And JAKInhibitor withdrawal is the worst experience I've ever had.
A snafu with my meds (which I now know was entirely my fault) has my next refill a week out. In the meantime I've been out since Sunday.
And JAKInhibitor withdrawal is the worst experience I've ever had.